NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment
September 27, 2023Research and Development Musculo-skeletal disorder, NMD Pharma, clinical trial, spinal muscular atrophy
NMD Pharma has announced that the first patient has been dosed in its phase 2 clinical trial for its CIC-1 …
Alfasigma to acquire Intercept Pharmaceuticals for $19 per share
September 27, 2023Business Services Alfasigma, Gastrointestinal tract, acquisition
Alfasigma and Intercept Pharmaceuticals have announced that they have entered into a definitive merger agreement, meaning Alfasigma will acquire Intercept …
Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review
September 26, 2023Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi
Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …
Acesion Pharma raises €45m series B funding
September 26, 2023Business Services Acesion Pharma, Cardiology, atrial fibrillation, series B financing
Acesion Pharma has announced that it has closed an oversubscribed €45m series B financing round. This financing was co-led by …
CDC Advisory Committee recommends Pfizer’s RSV vaccine
September 25, 2023Medical Communications Abrysvo, Immunology, Pfizer, RSV
Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has …
FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment
September 25, 2023Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease
Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …
FDA grants ODD to Nexcella’s NXC-201 as treatment for amyloid light chain amyloidosis
September 22, 2023Medical Communications FDA, Haematology, Nexcella, amyloidosis
Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NXC-201 for …
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial
September 22, 2023Research and Development AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) …
Novo Nordisk partners with UNICEF to prevent global childhood obesity
September 21, 2023Medical Communications Novo Nordisk, Obesity, Unicef, childhood obesity
Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent global childhood obesity, which is …
EC approves Menarini Group’s Orserdu for breast cancer treatment
September 21, 2023Medical Communications European Commission, Oncology, Orserdu, breast cancer
The Menarini Group and its subsidiary Stemline Therapeutics have announced that the European Commission (EC) has approved Orserdu (elacestrant) as …
Pharmanovia acquires CNS portfolio from Sanofi
September 20, 2023Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition
Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …
Exscientia enters AI drug discovery collaboration with Merck KGaA
September 20, 2023Business Services AI, Exscientia, Immunology, Merck KGaA, Neurology, Oncology, collaboration, drug discovery
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on the discovery of novel small …
EC approves Pfizer’s Litfulo for adolescents and adults with alopecia
September 19, 2023Medical Communications Dermatology, EC, Litfulo, alopecia
Pfizer has announced that the European Commission (EC) has granted marketing authorisation to Litfulo (ritlecitinib) to treat adult and adolescent …
BioNTech and CEPI partner for development of mRNA mpox vaccine
September 19, 2023Research and Development BioNTech, CEPI, Immunology, mpox
BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a partnership to advance the development of mRNA-based vaccine …
GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia
September 18, 2023Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …
Astellas plans to invest over €330m in new facility in Ireland
September 18, 2023Manufacturing and Production Astellas Pharma, Ireland, Pharmacy, facility, manufacturing
Astellas Pharma has announced that it is preparing to submit a planning application to build a new state-of-the-art facility at …
GSK and Save the Children extend partnership for unvaccinated children
September 15, 2023Medical Communications GSK, Immunology, childhood vaccination, vaccines
GSK and Save the Children have announced that they will be renewing their partnership for an additional five years. GSK …
BMS shares new research and development  plans at the company’s R&D day
September 15, 2023Research and Development BMS, Pharmacy, R&D, development, research
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, US, in order to discuss …
Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India
September 14, 2023Sales and Marketing License Agreement, Neurology, Pharmazz, Sun Pharma, Tyvalzi, sovateltide
Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a license agreement with Pharmazz in …
Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA
September 14, 2023Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom
Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …
Latest content
FibroFind appoints Lee Borthwick as CEO
